Teriparatide in east asian postmenopausal women with osteoporosis in a real-world setting: A baseline analysis of the Asia and Latin America fracture observational study (ALAFOS)

Chung Hwan Chen, Seung Jae Lim, Jong Keon Oh, Tsan Wen Huang, Yuhong H. Zeng, Meng Ting Wu, Huilin L. Yang, Jason Pui Yin Cheung, Ji Wan Kim, Jeong Hee Han, Li Huo, Tsung Jung Lin, Gang Zhou, Wen Shuo Wu

    Research output: Contribution to journalArticlepeer-review

    7 Citations (Scopus)


    Purpose: The aim of this analysis is to describe the baseline characteristics of patients who are prescribed teriparatide for the treatment of postmenopausal osteoporosis in a real-world setting in East Asia. Patients and Methods: The Asia and Latin America Fracture Observational Study (ALAFOS) is a prospective, multinational, observational study designed to evaluate real-world use of teriparatide in the treatment of postmenopausal osteoporosis in 20 countries across Asia, Latin America, the Middle East, and Russia. This subregional analysis focuses on the East Asian subpopulation of the ALAFOS study. Here we report baseline clinical characteristics, details regarding the history of fractures, risk factors for osteoporosis, comorbidities, osteoporosis treatment, and health-related quality of life in patients enrolled in China, Hong Kong, South Korea, and Taiwan. Results: The East Asian subgroup of ALAFOS included 1136 postmenopausal women, constituting 37.5% (1136/3031) of the overall ALAFOS patient population. The mean (SD) age was 75.0 (9.6) years. The mean (SD) bone mineral density T-scores were −3.11 (1.54), −2.58 (1.11), and −2.86 (1.09) at the lumbar spine, total hip, and femoral neck, respectively; 69.6% of patients had experienced at least one fragility fracture and 40.4% had experienced ≥2 fragility fractures after 40 years of age. Overall, 63.3% of patients had used medications for osteoporosis in the past. The mean (SD) EQ-5D-5LVisual Analog Scale (VAS) score at baseline was 59.7 (20.8); the mean (SD) back pain numeric rating scale score for worst pain in the last 24 hrs was 5.2 (3.2). Conclusion: Our results indicate that patients who are prescribed teriparatide in East Asia were elderly women with severe osteoporosis, low bone mineral density, high prevalence of fractures, back pain and poor health-related quality of life. Most of the patients received teriparatide as a second-line treatment.

    Original languageEnglish
    Pages (from-to)111-121
    Number of pages11
    JournalClinical Interventions in Aging
    Publication statusPublished - 2020

    Bibliographical note

    Funding Information:
    The authors thank Fernando Marin (MD, PhD), global study physician, Thomas Moll (PhD, MBA), clinical trial manager, Alan Brnabic (MSc), study statistician, and Sheetal Pradhan (MD), medical writer, for their contributions to this manuscript. All are employees of Eli Lilly and Company. The authors also thank Ms. Sin Ting Lau for her help in study support. Eli Lilly and Company sponsored the ALAFOS study. Unique study identifier for the ALAFOS study: B3D-MC-B026.

    Publisher Copyright:
    © 2020 Chen et al.


    • East Asia
    • Fractures
    • Observational study
    • Postmenopausal osteoporosis
    • Teriparatide

    ASJC Scopus subject areas

    • Geriatrics and Gerontology


    Dive into the research topics of 'Teriparatide in east asian postmenopausal women with osteoporosis in a real-world setting: A baseline analysis of the Asia and Latin America fracture observational study (ALAFOS)'. Together they form a unique fingerprint.

    Cite this